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Summary The synthesis and degradation of type I and type IlIl interstitial collagens releases several antigenic metabolites, whose
measurement allows the metabolism of connective tissue to be evaluated under a variety of different conditions. In this study we investigated
the influence of benign and malignant ovarian neoplasms on the metabolism ofthese collagens. The study population comprised patients with
benign (n = 53), borderline (n = 6) or malignant (n = 36) ovarian neoplasms. We quantified the serum, cyst fluid and peritoneal/ascitic fluid
concentrations of the amino-terminal propeptide of type (PINP) and IlIl (PIIINP) procollagens, indicators of the synthesis of type and IlIl
collagen, respectively and the cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), aniindicator of type I collagen degradation.
Macrophage colony-stimulating factor 1 (CSF-1) concentration was also assayed as its serum level is increased in ovarian cancer and CSF-
1 may be involved in the regulation of collagen metabolism. The concentration of each antigen was significantly higher in patients with
malignant tumour than with benign neoplasm in each comparison, except for ICTP in peritoneal fluid and for CSF-1 in cyst fluid. The high
ascitic fluid concentration of PINP, PIIINP or CSF-1 correlated with malignancy, and the low cyst fluid concentration of any of the four markers
was indicative of benign tumour. Levels of CSF-1 did not correlate with the levels of any of the markers of collagen turnover. The
concentration of PINP in ascites was about 50 times higher and in cyst fluid about eight times higherthan that in the serum from patients with
malignant tumour, whereas the respective ratios for ICTP were only 2.5 and 1.3. In such patients, the ratio of ascitic fluid to serum
concentration was also about 80-fold higher for PIIINP and about 20-fold higher for PINP than for ICTP. The different distributions of PIIINP,
PINP and ICTP suggests dominance of synthetic processes or retarted elimination of PIIINP and PINP in ovarian cancer. In advanced
malignancies, the accumulation of PINP and PIIINP in abdominal space, possibly due to increased synthesis and/or failed resorption, may
promote ascites formation. This study shows that both accelerated synthesis and breakdown of fibrillar collagens are characteristic of ovarian
malignancy, and suggests that measurements of cyst fluid or ascitic fluid concentrations of collagen metabolites or CSF-1 could be used in
the differential diagnosis of benign and malignant ovarian neoplasms.
Keywords: matrix reaction; type collagen; type IlIl collagen; macrophage colony-stimulating factor 1; tumour-associated marker;
ascites formation
The growth and dissemination ofmalignant neoplasms are accom-
panied by complex biochemical events that alter collagen metabo-
lism. During tumour growth and dissemination the increased
synthesis ofproteolytic enzymes with the consequentdisruption of
collagen architecture is a prerequisite for neoplastic cell invasion
and dissemination (Liotta, 1986; van den Hooff, 1986). Proteolytic
phenomena have been the subject ofintensive research for over 10
years (Liotta, 1986; van den Hooff, 1986). However, much less
research has focused on the synthesis of extracellular collagens,
even although fibrillar collagens are essential components of the
extracellular matrix ofany tumour. In addition, extensive collagen
synthesis is characteristic ofthe so-called 'desmoplastic' reactions
that are often observed surrounding the neoplastic epithelial cells
ofmany solid tumours.
The most abundant soft-tissue collagens are types I and III. At
present, specific radioimmunoassays (RIAs) can be used to
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monitor both the synthesis oftype I and type III collagens, and the
degradation of type I collagen (Risteli et al, 1995). The amino-
terminal propeptides of type I (PINP) and type III procollagens
(PIIINP) are removed during the synthesis of the corresponding
collagens. Although some ofthese propeptides may remain on the
surface of the collagen fibres (Fleischmajer et al, 1985) and are
released into body fluids during degradation ofcollagenous matrix
network, present techniques measure predominantly the synthesis
of the corresponding collagen molecules (Risteli et al, 1988a;
Melkko et al, 1996). The trivalently cross-linked carboxy-terminal
telopeptide of type I collagen (ICTP) is a degradation product of
the mature type I collagen molecule.
We have previously investigated synthesis of type III collagen
with our assay for PIIINP (Risteli et al, 1988b; Kauppila et al,
1989) and that of type I collagen using an assay we have devel-
oped that measures levels of the carboxy-terminal propeptide of
type I procollagen (PICP) (Zhu et al, 1993) in patients with
ovarian neoplasms. In this study we widened our investigations by
the inclusion oftwo new markers; PINP and ICTP. The quantifica-
tion of levels of the last two antigens enabled us for the first time
to measure simultaneously both the synthesis as well as the degra-
dation oftype I collagen in this disease, and to compare synthesis
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Figure 1 Dot plot depicting individual concentrations of intact PINP, ICTP and PIIINP in patients with malignant (0, left of panels), borderline (x, middle of
panels) or benign (U, right of panels) ovarian tumour. The solid line represents the median. Number of subjects below the dot plots for malignant, borderline and
benign tumours, and P-values of comparisions between malignant and benign specimens are also presented. NS, not significant
of type I and type III collagens using PINP and PIIINP, which are
synthesized and degraded by similar mechanisms. Serum, peri-
toneal/ascitic fluid and cyst fluid specimens from ovarian tumour
patients were assayed for these markers.
The cytokine macrophage colony-stimulating factor 1 (CSF-1)
stimulates the proliferation and differentiation of monocytes, is a
chemoattractant for macrophages and may be involved in the
pathogenesis of ovarian and some other malignancies (Kacinski,
1995). Neoplastic epithelial cells synthesize CSF-1 and increase
CSF-l production through macrophage activation, which in turn
may stimulate further growth of the neoplasm, particularly when
the tumour cells themselves express receptors for this cytokine
(Kacinski, 1995). Further support for this approach comes from
observations that macrophage-conditioned media enhance stromal
cell proliferation (Olive et al, 1991). In endometrial carcinoma,
serum concentrations ofCSF- 1 were found to correlate with serum
PIIINP concentrations, suggesting a possible causal link between
PIIINP release and CSF-l synthesis (Hakala et al, 1995).
As CSF- 1 is known to be essential for macrophage survival and
macrophages play an essential role in fibrillar collagen catabolism
and CSF-I is synthesized often at very high levels by many epithe-
lial tumours of female reproductive organs, it was reasonable for
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Figure 2 Dot plot depicting individual concentration of CSF-1 in patients with malignant (0, left of panels), borderline (x, middle of panels) or benign (, right
of panels) ovarian tumour. The solid line represents the median. Number of subjects below the dot plots for malignant, borderline and benign tumours, and P-
values of comparisons between malignant and benign specimens are also presented. NS, not significant
us to determine whether or not CSF-l levels might correlate with
collagen breakdown products and perhaps with new collagen
synthesis as a consequence ofreparative collagen synthesis.
MATERIALS AND METHODS
Patients
Serum samples were obtained from 95 patients who underwent
surgery for ovarian tumours in the Department of Gynaecological
Oncology of Oulu University Hospital. Thirty-six of the tumours
were histopathologically malignant, six were borderline and 53
were benign. All malignant neoplasms were ofepithelial origin: 14
serous, eight endometrioid, seven mucinous, three clear cell, and
four undifferentiated. According to the classification of the
International Federation of Gynaecology and Obstetrics, 15
ovarian carcinomas were clinical stage I, one stage II, 18 stage III
and two stage IV disease. Seven tumours were well differentiated
(grade 1), ten moderately differentiated (grade 2) and 19 anaplastic
(grade 3). Ofthe borderline tumours, three were serous, two muci-
nous and one was a Brenner tumour. The benign tumours included
18 serous cystadenomas, 15 mucinous cystadenomas, six simple
cysts, three corpus luteum cysts, two parovarian cysts, two
Brenner tumours and seven fibromas. From the same patients,
peritoneal fluid or ascitic fluid and/or cyst fluid samples were
collected as follows: malignant ascites from 27 patients, peritoneal
fluid from three patients with borderline tumour and six patients
with benign tumours. The numbers of cyst fluid samples from
malignant, borderline and benign tumours were 15, 5 and 48
respectively. The median age of the patients was 56 years (range
22-86 years), with no difference between those with malignant or
benign tumours.
Blood samples were obtained at the diagnostic work-up within 2
weeks before surgery. Peritoneal/ascitic fluid and ovarian cyst
fluid samples were collected during the operation. All the samples
were immediately frozen and stored at - 20°C until assayed.
Radioimmunoassays
PINP, ICTP and PIIINP concentrations were determined by
equilibrium radioimmunoassays for the human antigens. The
radioimmunoassay kits for intact PINP, ICTP and PIIINP were
purchased from Orion Diagnostica (FIN-90460 Oulunsalo,
Finland). The upper limits ofthe reference interval for serum PINP,
ICTP and PIIINP were 79 jig 1-', 4.6 ,ug 1-1 and 4.2 gg 1-' respec-
tively. Serum samples of 25 ovarian cancer patients were also
assayed withthe PINP Col 1 (amino-terminal globularregion ofthe
amino-terminal propeptide of type I) method, which also detects
small-molecular-weight degradation products of PINP molecules
(Risteli et al, 1995; Melkko et al, 1996). The samples for CSF-1
determination were sent frozen to the laboratory in the USA (ERS).
CSF-1 was quantified by radioimmunoassay using methods
described in detail elsewhere (Gilbert et al, 1989). The upper limit
ofthe reference interval for serum CSF- 1 was 6.1 jig 1-'.
Statistical analysis
Because ofthe skewed distribution of most variables, we used the
Mann-Whitney U-test throughout in the bivariate comparisons. A
dot-plot technique was used to present the distribution of the
markers. A linear regression model was applied to estimate the
relationship between two continuous variables.
RESULTS
Malignant and benign tumours
Comparison of intact PINP, ICTP, PIIINP and CSF-1 in samples
from patients with malignant and benign tumours revealed signifi-
cantly higher concentrations in specimens from ovarian carcinoma
patients in all levels, except those ofICTP in the peritoneal/ascitic
fluid and CSF-1 in the cyst fluid (Figures 1 and 2). Despite the
remarkable overlap of the values between the groups, the present
results demonstrate that high peritoneal fluid PINP (> 2500 jig 1-'),
PIIINP (> 400 jig 1-1) or CSF-1 (> 8 jig 1-1) concentration is
characteristic of malignancy, whereas low cyst fluid PINP
(< 300 jig 1-1), ICTP (< 0.5 jig 1-1), PIIINP (< 30 jg 1-1) or CSF-1
(<1 jIg 1-l) concentration is typical ofbenign neoplasms.
The median PINP concentration in ascitic/peritoneal fluid from
individuals with a malignant disease was approximately 50 times
higher and in cyst fluid eighttimes higherthan that in serum (Table
1). ICTP concentration in ascitic/peritoneal fluid was only 2-3
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Table 1 The ratio of PINP, ICTP, PIIINP and CSF-1 in peritoneal fluid and in
cyst fluid in relation to serum level and between peritoneal and cyst fluid of
the respective marker. Number of specimens and the median concentration
of any marker are given in Figures 1 and 2
Marker PINP ICTP PIIINP CSF-1
Peritoneal fluid/serum
Malignant 50 2.5 200 1.4
Benign 18 3.5 50 0.8
Cyst fluid/serum
Malignant 8.1 1.3 30 1.5
Benign 3.4 1.0 12 1.3
Peritoneal fluid/cyst fluid
Malignant 6.1 1.9 6.7 0.9
Benign 5.3 3.5 4.3 0.6
times higher than in serum and remarkably similar in cyst fluid
and in serum from both groups of patients. PIIINP concentration
was 200-fold higher in ascitic fluid and 30-fold higher in cystfluid
than that in serum from patients with malignant disease. The
median PINP and PIIINP concentration in malignant ascites was
on average six- to sevenfold higher than in cyst fluid. The median
CSF-1 concentration was about 1.5-fold higher in ascitic fluid and
in cyst fluid than in serum from patients with malignant ovarian
tumour and remarkably similar in serum, peritoneal fluid and cyst
fluid from patients with a benign tumour.
The data for the six patients with borderline malignancies,
presented in Figures 1 and 2, were not used in any statistical
evaluation. The values for borderline tumours were mostly in the
same range as those of benign tumours in the serum and peri-
toneal/ascitic fluid, whereas in the cyst fluid they were predomi-
nantly ofthe same category as the values in malignant tumours.
Correlations
In patients with a malignant tumour, serum ICTP concentration
correlated significantly with that in malignant ascites (Figure 3)
but not with that in cyst fluid. There was also a significant correla-
tion between the concentration of PINP, but not of PIIINP, in
serum and malignant ascites (Figure 3). The concentration of
PIIINP and CSF-1 in ascites or in cyst fluid did not correlate with
each other or with serum concentration of any marker. A strong
correlation between the concentration of PINP and PINP Col 1
(R2 = 0.82, P = 0.82), and quite similar median levels ofPINP Col
1 (58 gg 1-1) (range 25-174) and PINP concentration (47 gg 1-1)
(range 16-112) in sera from 25 patients with malignant tumour
demonstrated that the majority of PINP molecules in serum
appeared in the form ofintact PINP.
Clinical findings
The serum concentrations ofintact PINP, ICTP, PIIINP and CSF-1
were increased in 10%, 57%, 60% and 50% of patients with
ovarian cancer, respectively, without any substantial difference
between stages I plus II and stages III plus IV (Figure 4) (data not
shown for CSF-1). There was also no significant difference in any
marker level between the subtypes of epithelial carcinomas. The
serum concentrations of PINP and PIIINP but not those of ICTP
(Figure 4) and CSF-1 (grade 1-2: n = 17, median concentration
4.7 jg 1-1, range 0.4-15 jg 1-1; grade 3: n = 19, median concentra-
tion 8.9 jg 1-1, range 0.3-19 jig 1-1) were significantly higher in
patients with grade 3 carcinomas than in patients with grade 1-2
carcinomas, suggesting that poorly differentiated tumours stimu-
late synthesis of fibrillar collagens more than well-differentiated
neoplasms do.
DISCUSSION
In this study we used fluid specimens for the intact PINP, ICTP,
PIIINP and CSF-1 assays from three sources: ovarian cyst, peri-
toneal cavity and circulation. The levels of these markers in cyst
fluid very probably reflect matrix reactions within the tumour; in
peritoneal/ascitic fluid their levels may be consequent to tumour-
induced reactions within the peritoneal cavity, whereas those
observed in the serum may originate from the tumour, from the
peritoneal cavity, from the reactions of the host to ovarian
neoplasm or from all of these. In the interpretation of the results,
we have put a special emphasis on (a) parallel investigation of
synthesis andbreakdown oftype I collagen; (b) parallel evaluation
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Figure 3 Linear relationship between the serum and ascitic PINP and ICTP concentrations in the ovarian cancer patients
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Stage The concentration of PINP was significantly higher in the
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NS . 520 than in those with benign tumour, a finding that agrees with the 120 * results on PICP, another indicator of synthesis of type I collagen
100 (Zhu et al, 1993). On the otherhand, ICTP was significantly higher
only in serum and cyst fluid but not in peritoneal fluid. Serum
80 . ICTP antigen is assumed to result predominantly from the catabo-
lism of mature type I collagen in the skeleton (Risteli and Risteli,
60 @ * * 1993) and has proven useful in detection ofbone metastases and in
40 * ; monitoring their response to therapy (Kylmala et al, 1995).
*o * * @ Destruction ofsoft tissues also contributes to the blood pool ofthis
20 * antigen, and serum ICTP behaves like a tumour marker in
0 advanced ovarian cancer(Santala etal, 1995). Because the present
St 1-11 St III-IV assay identifies only telopeptides with trivalent cross-links it does
n=12 n= 17 not detect degradation products of newly formed (Risteli et al,
1997), less cross-linked type I collagen common in tumour tissue
(Kauppila et al, to be published) and within the peritoneal cavity of
NS@o31 patients with this illness. Therefore, based on ascites to serum
* 22 ICTP and PINPcorrelations, ICTP may be an indicator ofinvasive
16 * growth as the existing, old connective tissue is more cross-linked
than that induced by cancer. This might explain why in relative
terms the difference between malignant and benign tumours was
12 much smaller for ICTP than PINP.
The presence ofPINPtogether with PIIINP in higherconcentra-
8 * . * tions in ascites than in cyst fluid suggests that the malignant
tumour stimulatesfibroproliferative reactions within theperitoneal
4 . cavity more than in tumour tissue. This novel finding here and
*0 * * @@ previously (Zhu et al, 1993) suggests that ovarian cancer strongly
0 . enhances synthesis of fibrillar collagens, in particular within the
St-1 St I-V peritoneal cavity. In fact, the rich intraperitoneal accumulation of
n= 12 n= 16 collagenous components might biochemically mimic the desmo-
plastic reaction of the tissue surrounding solid tumours. The
increased PINP concentration in ascitic fluid relative to that of
serum concentration was not as striking as that of PIIINP because
.22 the basal production of PINP by bone turnover may mask the
NS 18 impact of the malignancy-induced increase in type I collagen
12 synthesis in the circulation but not within the peritoneal cavity.
10 The ratio of ascitic fluid to serum concentration was about 80-
* fold higher for PIIINP and about 20-fold higher for PINP than for
8 . . ICTP in ovarian cancerpatients. The difference, which stresses the
6 * significance ofsynthetic processes, may have many reasons. First,
* ., ,. ICTP may be diffused into the circulation more effectively than
4. PINP or PIIINP. A strong correlation between serum and ascitic
2 * @* fluid ICTP concentrationtogether with a lack ofsuch acorrelation
for PIIINP supports this view. ICTP has a small molecular weight
0 (12 000 prepared by bacterial collagenase digestion, 20000
St 1-11 St III-IV prepared by trypsin digestion) relative to the molecular weight of
n = 15 n = 20 PINP (35 000) and PIIINP (42 000). In addition, the propeptide
molecules detected in PIIINP assay are often present in the ascitic
concentrations of ovarian cancer fluid in an unprocessed, immature form of very large molecular
grade and clinical stage. The size (Zhu et al, 1994). The lymphatics are also important for the
al value. Gr, grade; St, stage; resorption of PIIINP molecules from abdominal cavity (Jensen et
al, 1993). Any interruption of this route by malignancy may
prevent the procollagen molecules to reach the circulation.
II collagens using assays Second, ICTP and the procollagen propeptides are cleared by
respective molecules, which different mechanisms. The ICTP antigens are cleared from the
-ndothelial scavenger recep- blood by the kidneys (Risteli and Risteli, 1995), whereas PIIINP
pe I and type III procollagen and PINP are eliminated by the scavenger receptors of the liver
r ascites formation; (d) the endothelial cells (Risteli et al, 1995). Third, the low ascitic
en metabolism; and (e) the fluid-serum concentration ratio of ICTP may reflect a low rate of
ays. degradation relative to the rate of its synthesis in this disease in
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general. Alternatively, this finding is specific only for the condi-
tions the specimens were taken as ascites was mostly from patients
who were operated on soon after its appearance. At this stage,
tumours usually manifest a rapid intra-abdominal growth rate.
Because PINP may be degraded to smaller antigenic forms in
patients with catabolic status (Risteli et al, 1995), we evaluated in
more detail the PINP molecules in the serum from patients with
malignant ascites using the PINP Col 1 assay, which measures
both the intact propeptide and its degradation products. This assay
gave only slightly increased concentrations relative to the assay
for intact PINP, confirming that the latter assay is reliable for
comparisons of serum and ascitic fluid PINP concentrations.
CSF-1 might be causally linked to enhanced collagen metabo-
lism in ovarian cancer (Jennings et al, 1994), as we had supposed
to be the case for endometrial cancer (Hakala et al, 1995).
Malignant cells may activate the cells of the immune systems to
release growth factors and cytokines to stimulate collagen metabo-
lism. Ovarian cancer cells could also activate macrophages, e.g. by
CSF-1 (Kacinski, 1992, 1995), which are known to stimulate
collagen production in the fibroblastic cells (Sporn and Roberts,
1992). However, our present results do not support the concept
that CSF-1 regulates either the synthesis or the degradation of
fibrillar collagens in ovarian cancer. The finding that different
cancer cell lines secrete differing amounts of CSF-1 (Kacinski,
1995), and that ovarian and endometrial cancer behave differently
in this respect, may explain the conflicting finding.
CSF-1 has an important role in the regulation of the neoplastic
disease activity of ovarian cancer (Kacinski, 1992, 1995), and it
has potential to be a practical tumour marker in patients with
gynaecological (Kacinski et al, 1989, 1990; Hakala et al, 1995)
and other malignant diseases (Janowska-Wieczorek et al, 1991).
We have confirmed here that CSF-I concentration in ascitic fluid
is increased in patients with ovarian carcinoma (Kacinski, 1992,
1995; Price et al, 1993). The present median concentration of
CSF-I in ascites was the same as in the study ofPrice et al (1993).
Serum CSF-1 concentrations were elevated only in 50% of the
present patients. The higher frequency, approximately 70% in
previous reports on patients with clinically detectable ovarian
carcinoma, is possibly due to different patient populations.
We also showed that high concentration of CSF-1 (8,g 1-' or
more), PINP (2500 jig 1-' or more) or PIIINP (400,g 1-1 or more) in
peritoneal fluid is diagnostic ofovarian cancer. On the other hand,
low cyst fluid values of any marker is indicative of benign tumour.
The measurement of the ascitic and cyst fluid concentration of
CSF- 1 or any of the above-mentioned antigenic collagen metabo-
lites might help differentiate benign from malignant tumours.
The grade ofdifferentation of the tumour was a more important
determinant for the expression of type I and type III collagen
metabolites than the extent of disease. The concept that the
synthesis of fibrillar collagens is most evident in anaplastic
ovarian malignancies gets supports from our immunohistochem-
ical studies (Zhu et al, 1995) and investigations applying in situ
probes for ot1 and a2 chains oftype I collagen and fora1 oftype III
collagen (Kauppila et al, 1996). Besides the fibroblasts, some
anaplastic malignant cells seem to participate in the synthesis of
collagen fibres (Zhu et al, 1995; Kauppila et al, 1996). The
mesothelial cells in the peritoneum also probably contribute to
these reactions with growth factor (e.g. CSF-1) expression
(Jennings et al, 1994). The expression of the enzymes responsible
for the destruction of fibrillar collagens is also most prominent in
anaplastic tumours (Autio-Harmainen et al, 1993).
In conclusion, our study provides several independent lines of
evidence demonstrating that the greatly enhanced synthesis of
fibrillar collagens is a characteristic of ovarian malignancy, as is
the simultaneously enhanced breakdown of soft tissue and its
collagenous framework.
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